EUCLIDEAN CAPITAL LLC
Q2 2025 Form 13-F

NEW YORK, NEW YORK
CIK 0001825034 · Institutional investment manager
$305.7M Reported Value Total
Reported value
$305.7M
Quarter over quarter
+11.2%
Holdings
11
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Joseph Cosmai
Manager

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2025 13F record

Q2 2025 13F filing summary

Q2 2025 Form 13F portfolio summary
Period of report June 30, 2025
Filed August 14, 2025
Form 13F-HR
Reported value $305.7M
Positions 11
Change in reported value +14.9%
New positions 1
Exited positions 1
Position turnover 16.7%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
10 $323.6M
Q2 2026 13F
Filed Aug 14, 2026
11 $439.8M
Q1 2026 13F
Filed May 15, 2026
10 $392.3M
Q4 2025 13F
Filed Feb 17, 2026
12 $369.5M
Q3 2025 13F
Filed Nov 14, 2025
11 $238.0M
Q2 2025 13F
Filed Aug 14, 2025
11 $305.7M
Q1 2025 13F
Filed May 15, 2025
11 $266.1M
Q4 2024 13F
Filed Feb 14, 2025
11 $736.7M
Q3 2024 13F
Filed Nov 14, 2024
12 $906.8M
Q2 2024 13F
Filed Aug 14, 2024
11 $795.8M
Q1 2024 13F
Filed May 15, 2024
13 $780.0M
Q4 2023 13F
Filed Feb 14, 2024
13 $888.5M
Q3 2023 13F
Filed Nov 14, 2023
13 $458.4M
Q2 2023 13F
Filed Aug 14, 2023
12 $389.1M
Q1 2023 13F
Filed May 15, 2023
10 $114.0M
Q4 2022 13F
Filed Feb 14, 2023
11 $106.9M
Q3 2022 13F
Filed Nov 14, 2022
10 $107.7M
Q2 2022 13F
Filed Aug 15, 2022
10 $117.6M
Q1 2022 13F
Filed May 16, 2022
11 $172.1M
Q4 2021 13F
Filed Feb 14, 2022
11 $175.9M

4 earlier quarters on file — choose one from the quarter menu above.

Top 11 holdings · Q2 2025

Largest Q2 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 VEU VANGUARD INTL EQUITY INDEX F $144.0M 47.11%
2 INDA ISHARES TR $135.0M 44.17%
3 ORIC ORIC PHARMACEUTICALS INC $10.0M 3.28%
4 FHTX FOGHORN THERAPEUTICS INC $7.4M 2.42%
5 PMVP PMV PHARMACEUTICALS INC $2.8M 0.91%
6 SPY SPDR S&P 500 ETF TR $2.5M 0.83%
7 ALEC ALECTOR INC $1.8M 0.6%
8 SRZN SURROZEN INC $784.0K 0.26%
9 RAPT RAPT THERAPEUTICS INC $657.9K 0.22%
10 TNYA TENAYA THERAPEUTICS INC $620.8K 0.2%
11 SRZNW SURROZEN INC $3.1K < 0.01%

Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings